<DOC>
	<DOCNO>NCT01946165</DOCNO>
	<brief_summary>The goal clinical research study learn add combination abiraterone acetate prednisone without enzalutamide hormonal therapy help control prostate cancer give surgery . The safety drug combination also study .</brief_summary>
	<brief_title>Abiraterone Acetate Plus LHRH Agonist Abiraterone Acetate Plus LHRH Agonist Enzalutamide</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , randomly assign ( like roll dice ) 1 2 group . You 2 3 chance assign Group A 1 3 chance assign Group B . If Group A , receive hormonal therapy ( LHRH ) , abiraterone acetate , prednisone , enzalutamide . If Group B , receive LHRH , abiraterone acetate , prednisone . Study Drug Administration : The study doctor decide hormone therapy receive , explain take , explain risk . In addition , take 4 abiraterone acetate tablet mouth day ( time ) least 1 hour meal 2 hour meal . You also take 1 tablet prednisone mouth 1 time day help low risk side effect cause abiraterone acetate . If Group A , also take 4 capsule enzalutamide mouth day . You take enzalutamide time every morning . Enzalutamide take without food . If miss dose , NOT take another dose next day . You tell study doctor soon possible miss dose . About every 28-days call cycle . You return unused study drug and/or empty pill bottle end cycle . Study Visits : On Day 1 Cycle 1 : - You physical exam . - Blood ( 3-4 tablespoon ) draw routine test check PSA level . On Day 15 Cycles 1 , 2 3 , blood ( 2 tablespoon ) draw check liver function . These test may do local doctor 's office result fax MD Anderson . On Day 1 Cycles 2 , 3 , 4 , 5 6 : - You physical exam . - Blood ( 3-4 tablespoon ) draw routine test . This blood also use check PSA level . The test Cycles 2 , 4 6 may do local doctor 's office result fax MD Anderson . Within 14 day surgery End Treatment Visit : - You physical exam . - Blood ( 3-4 tablespoon ) urine collect routine test . This blood also use check PSA level , blood sugar level , blood-clotting function . You ask fast least 8 hour blood draw . - You chest x-ray CT scan chest . - You EKG check heart function . Surgery : After 6 cycle study treatment , surgery remove prostate . You ask sign separate consent form surgery , risk discuss . Your leftover prostate gland tissue surgery collect used biomarker test . About 4 8 week surgery : - You physical exam . - Blood ( 3-4 tablespoon ) draw routine test . This blood also use check PSA , testosterone , cholesterol , blood sugar level . Length Study : You may receive study drug 6 month . You take study early disease get bad , intolerable side effect , study doctor think best interest stop , unable follow study direction . Your participation study complete visit surgery . This investigational study . Abiraterone acetate FDA approve combination prednisone treatment patient metastatic castration-resistant prostate cancer receive prior chemotherapy contain docetaxel . Prednisone FDA approve commercially available corticosteroid . Enzalutamide FDA approve commercially available treatment certain type prostate cancer . Their combination hormone therapy patient prostate cancer investigational . Up 69 patient enrol study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>1 . Be willing/able adhere prohibition restriction specify protocol 2 . Have sign inform consent document indicate subject understand purpose procedure require study willing participate study 3 . Written Authorization Use Release Health Research Study Information obtain . 4 . Male age &gt; /=18 year . 5 . Histologically cytologically confirm adenocarcinoma prostate histological variant ( small cell , sarcomatoid , pure ductal cancer , transitional cell carcinoma ) . 6 . Pathology review treat academic institution member institution ( Note : patient 's prostate biopsy read treat institution , must review study site confirm eligibility ) . 7 . At least three core biopsy involve cancer ( minimum 6 core biopsy must obtain baseline ) . A prostate biopsy within 3 month screen allow entry requirement . Patients must Gleason score &gt; 5 ( total ) . 8 . At least one follow feature : ) PSA &gt; 10 ng/ml ; b ) PSA velocity &gt; 2 ng/ml/year ( define rise PSA &gt; 2 ng/ml precede 12 month period ) ; c ) Gleason score &gt; /= 7 ; ) Gleason score 6 either PSA &gt; /= 10 ng/ml PSA velocity &gt; /=2 ng/ml/year 9 . Serum testosterone &gt; 200 ng/dL . For patient treat 1 month LHRH agonist , testosterone measurement prior LHRH treatment use determine eligibility , must &gt; 200 ng/dL . 10 . Urologist must agree patient suitable prostatectomy . 11 . No evidence metastatic disease determine imaging procedure . 12 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . 13 . Hemoglobin &gt; /= 10.0 g/dL independent transfusion . 14 . Platelet count &gt; /=100,000/ÂµL . 15 . Patients adequate bone marrow function define absolute peripheral neutrophil count ( ANC ) &gt; /= 1,500 . 16 . Creatinine clearance &gt; /= 60 mL/min 17 . Serum potassium &gt; /= 3.5 mmol/L . 18 . Serum albumin &gt; /= 3.5 g/dL . 19 . Liver function test serum bilirubin &lt; /= 1.5x ULN ALT AST &lt; /= 1.5x ULN . 20 . Able swallow study drug whole tablet . 21 . Patients must normal coagulation profile history substantial non iatrogenic bleeding diathesis . 22 . Agree use doublebarrier method contraception involve use condom combination one following : contraceptive sponge , diaphragm , cervical ring spermicidal gel foam , sex woman childbearing potential length study one week abiraterone discontinue least three month enzalutamide discontinue . 23 . Willing take abiraterone acetate empty stomach ; food consume least two hour least one hour dose abiraterone acetate take . 1 . Serious uncontrolled coexistent nonmalignant disease , include active uncontrolled infection . 2 . Chronically uncontrolled hypertension , define conventionally consistent systolic pressure 140 diastolic pressure 90 despite antihypertensive therapy . Note NOT criterion relate particular BP result time assessment eligibility , apply acute BP excursion related iatrogenic cause , acute pain transient , reversible cause . 3 . Requirement corticosteroid great equivalent 5 mg prednisone daily . 4 . Poorly control diabetes define Hemoglobin A1C &gt; 7.0 screening . 5 . Active symptomatic viral hepatitis chronic liver disease . 6 . History pituitary adrenal dysfunction . 7 . Clinically significant cardiovascular disease include : ) Myocardial infarction within 6 month Screening visit ; b ) Uncontrolled angina within 3 month Screening visit ; c ) Congestive heart failure New York Heart Association ( NYHA ) class 3 4 , subject history congestive heart failure NYHA class 3 4 past , history anthracycline anthracenedione ( mitoxantrone ) treatment , unless screen echocardiogram multigated acquisition scan ( MUGA ) perform within three month Screening visit result leave ventricular ejection fraction &gt; /= 50 % ; ) History clinically significant ventricular arrhythmia ( e.g. , ventricular tachycardia , ventricular fibrillation , torsade de pointes ) ; e ) Prolonged correct QT interval Fridericia correction formula ( QTcF ) screen Electrocardiogram ( ECG ) &gt; 470 msec ; f ) History Mobitz II second degree third degree heart block without permanent pacemaker place ; 8 . ( Exclusion # 7 continue ) : g ) Hypotension ( systolic blood pressure &lt; 86 mmHg bradycardia heart rate &lt; 50 beat per minute Screening ECG , unless pharmaceutically induce thus reversible ( i.e . beta blocker ) . 9 . Other malignancy , except nonmelanoma skin cancer , active &gt; /= 30 % probability recurrence within 12 month . 10 . History gastrointestinal disorder ( medical disorder extensive surgery ) may interfere absorption study drug . 11 . Prior hormone therapy prostate cancer include orchiectomy , antiandrogens , ketoconazole , estrogens ( 5alpha reductase inhibitor allow ) , LHRH agonists/antagonists ( *Note : LHRH allow begin within 1 month Day 1 ) . Patients previous current antiandrogen treatment great 4 week duration prior Cycle 1 Day 1 eligible appropriate washout . 12 . Prior systemic treatment azole drug within four week Cycle 1 Day1 . 13 . Current enrollment investigational drug device study participation study within 30 day Cycle 1 Day 1 . 14 . Allergies , hypersensitivity , intolerance prednisone , LHRH analog excipients prednisone LHRH analog , abiraterone acetate enzalutamide . 15 . Previous use abiraterone acetate investigational CYP17 inhibitor ( e.g. , TAK700 ) . 16 . Previous investigational antiandrogens ( e.g. , Enzalutamide , BMS641988 ) . 17 . Patients receive anticoagulant therapy unable stop prior surgery . 18 . Condition situation , investigator 's opinion , may put patient significant risk , may confound study result , may interfere significantly patient 's participation study . 19 . Severely compromised immunological state , include positive human immunodeficiency virus ( HIV ) . 20 . Patients appropriate surgical candidate radical prostatectomy base evaluation coexistent medical disease compete potential cause death ( limited , unstable angina , myocardial infarction within previous 6 month , use ongoing maintenance therapy lifethreatening ventricular arrhythmia , uncontrolled hypertension ) . 21 . Prior chemotherapy , radiation immune therapy prostate cancer . 22 . Patients unable tolerate transrectal ultrasound . 23 . Concomitant therapy following : ) Chemotherapeutic , biologic , agent antitumor activity prostate cancer assign study drug ; b ) Antiandrogens ( steroidal nonsteroidal ) cyproterone acetate , flutamide , nilutamide , bicalutamide , etc . assign study drug ; c ) 5alpha reductase inhibitor finasteride , dutasteride , anabolic steroid , etc . ; ) Estrogens , progestational agent megestrol , medroxyprogesterone , DES , cyproterone , spironolactone &gt; 50 mg/kg , etc . ; e ) Androgens testosterone , dehydroepiandrosterone [ DHEA ] , etc . ; f ) Ketoconazole ; g ) Herbal product may decrease PSA level ( e.g. , saw palmetto ) 24 . Active infection medical condition would make prednisone/ prednisolone ( corticosteroid ) use contraindicate . 25 . Severe hepatic impairment ( ChildPugh Class C ) . 26 . History seizure condition may predispose seizure include , limited underlie brain injury , stroke , primary brain tumor , brain metastasis , alcoholism . Also , history loss consciousness transient ischemic attack within 12 month enrollment ( Day 1 visit ) . 27 . History significant bleeding disorder unrelated cancer , include : ) Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) ; b ) Diagnosed acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) Screening visit ; c ) History GI bleed within 6 month Screening visit .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>High risk prostate cancer</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>Zytiga</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Enzalutamide</keyword>
	<keyword>MDV3100</keyword>
	<keyword>XTANDI</keyword>
	<keyword>Androgen ablation</keyword>
	<keyword>LHRHa</keyword>
	<keyword>Hormonal therapy</keyword>
</DOC>